Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2009 |
| End Date: | November 2011 |
A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
This is a Phase 1 open-label study evaluating the safety of navitoclax (ABT-263) when
combined with a standard regimen of gemcitabine in approximately 25 subjects with solid
tumors and measurable disease.
We found this trial at
3
sites
850 Boylston Street
Chestnut Hill, Massachusetts 02467
Chestnut Hill, Massachusetts 02467
1-800-BWH-9999
Brigham & Women's Hospital Women's Health Center At Brigham and Women
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials